Amyloid distribution study by high spec brain-dedicated PET

未提供0 个研究点目标入组 20 人开始时间: 2024年3月28日最近更新: 2025年3月5日

适应症

试验速览

暂无简介。

•Patients who complained of subjective cognitive decline and was suspected to be in the early stages of Alzheimer's disease according to the symptoms.
•Age at the time of informed consent is 40 to 80 years old, regardless of gender.
•Patients who had a score of 24 points or higher on MMSE conducted within 6 months before consent was obtained.
•Patients who are judged by the principal investigator to be capable of understanding the study explanation and consent document.

•History of hypersensitivity to alcohol.
•History of serious complications, medical or surgery.
•Patients currently taking medications; narcotics, psychotropic drugs, or anti-Parkinson's drugs.
•Taking medications for diabetes mellitus.
•Claustrophobia.
•People who have difficulty undergoing head MRI due to tattoos (including tattoos and permanent makeup), pacemakers, cochlear implants, etc.
•7.Patients who are pregnant or may be pregnant, or who are breastfeeding.
•8.Patient who is judged to be inappropriate as a participant by the principal or collaborating doctors

Comparison of mean cortical SUVR of amyloid PET

Comparison of mean cortical SUVR of amyloid PET using a brain-dedicated PET and a whole-body PET

Characteristics of Abeta and FDG brain distribution

Characteristics of Abeta and FDG brain distribution in amyloid PET positive cases

未报告次要终点

发起方

未提供